PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (300).
Saved in:
| Title: | PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (300). |
|---|---|
| Authors: | Secord, Angeles Alvarez1 (AUTHOR), Lewin, Sharyn2 (AUTHOR), Murphy, Conleth3 (AUTHOR), Method, Michael4 (AUTHOR) |
| Source: | Gynecologic Oncology. 2022 Supplement 1, Vol. 166, pS157-S158. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
